Indaptus Therapeutics is trading at $1.94 (+6.6%) in pre-market sessions, recovering from yesterday’s risk-off driven after-hours decline.
- The upward move appears tied to improving broader market sentiment and a rebound in U.S. equity futures rather than any new development specific to the company.
- There have been no fresh news releases, SEC filings, or analyst actions overnight to provide a company-specific catalyst for the price action.